| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥0.4B | ¥0.7B | -39.2% |
| Operating Income | ¥-2.5B | ¥-1.4B | -83.5% |
| Ordinary Income | ¥-2.2B | ¥-1.4B | -55.0% |
| Net Income | ¥-2.2B | ¥1.5B | -241.6% |
| ROE | -9.0% | 9.0% | - |
FY2026 Q3 results showed Revenue of 0.4B yen (YoY -39.2%), Operating Loss of -2.5B yen (YoY deterioration of -83.5%), Ordinary Loss of -2.2B yen (YoY -55.0%), and Net Loss of -2.2B yen (YoY -241.6%). Despite achieving a high gross profit margin of 89.1%, the company recorded substantial operating losses, primarily driven by selling, general and administrative expenses relative to the reduced revenue base. Cash and deposits remained robust at 24.2B yen, increasing 34.3% YoY, providing strong near-term liquidity despite the continued operating losses. The company recorded extraordinary income of 3.2B yen during the quarter, though this did not offset the underlying operational challenges. Full-year guidance projects continued losses with Revenue of 1.3B yen and Net Loss of -3.5B yen, with no dividend planned.
Revenue declined 39.2% YoY to 0.4B yen, reflecting significant contraction in sales volume or customer base. The company achieved gross profit of 0.4B yen with a gross margin of 89.1%, indicating strong product-level economics and minimal cost of goods sold. However, the transition from gross profit to operating loss of -2.5B yen (operating margin of -637.5%) demonstrates that selling, general and administrative expenses substantially exceeded gross profit generation. The magnitude of operating loss deepened by 83.5% YoY, suggesting that fixed cost structures were not adjusted proportionately to revenue decline. Non-operating income contributed 0.4B yen, including interest income of 0.02B yen and other non-operating gains, partially offsetting operating losses and resulting in ordinary loss of -2.2B yen. Extraordinary income of 3.2B yen was recorded, representing a non-recurring factor that improved reported results but does not reflect operational performance. The gap between ordinary loss of -2.2B yen and net loss of -2.2B yen was minimal, indicating negligible tax effects due to loss-making status. This represents a revenue down, profit down pattern driven by severe revenue contraction and insufficient cost structure adjustment.
[Profitability] ROE of -9.0%, reflecting net losses against equity base. Operating margin of -637.5% indicates substantial cost structure challenges relative to revenue scale. Net profit margin of -545.0% demonstrates deep operational losses. Gross margin of 89.1% remains strong, highlighting that product economics are sound but overhead costs overwhelm gross profit generation. [Cash Quality] Cash and deposits of 24.2B yen increased 34.3% YoY, providing coverage of 16.8x against short-term liabilities of 1.4B yen, indicating strong liquidity position. Receivables turnover days of 301 days reflects significant collection delays and working capital inefficiency. [Investment Efficiency] Asset turnover of 0.016 indicates extremely low revenue generation relative to asset base of 25.6B yen, suggesting substantial idle assets or development-stage operations. [Financial Health] Equity ratio of 94.4% reflects minimal financial leverage with equity of 24.2B yen. Current ratio of 1775.2% demonstrates exceptional short-term debt coverage capacity. Retained earnings of -10.5B yen accumulated losses, deteriorating 26.1% from prior year, representing ongoing capital erosion from sustained losses.
Cash and deposits increased 6.2B yen YoY to 24.2B yen, representing 34.3% growth and providing substantial liquidity cushion. The increase in cash occurred despite operating losses, suggesting potential equity financing or proceeds from asset disposals contributing to cash accumulation. Trade receivables of 0.3B yen with collection period of 301 days indicate significant working capital tied up in uncollected revenues, though absolute amounts remain modest. Current liabilities of 1.4B yen are well covered by cash holdings at 16.8x coverage ratio, eliminating near-term liquidity concerns. The disconnect between operating losses and strong cash position suggests that cash generation is not derived from core operations but rather from financing activities or non-recurring proceeds. Working capital efficiency requires attention given the extended receivables collection cycle, which constrains operational cash conversion despite low absolute receivables values.
Ordinary loss of -2.2B yen versus operating loss of -2.5B yen shows non-operating net contribution of approximately 0.3B yen, primarily comprising interest income of 0.02B yen and other non-operating gains of 0.4B yen. Non-operating income represents 97.5% of revenue, consisting mainly of financial income likely earned on substantial cash holdings of 24.2B yen. Extraordinary income of 3.2B yen was recorded during the period, representing a significant non-recurring item that artificially improved reported results but does not reflect sustainable earning power. Without this extraordinary gain, underlying losses would have been substantially deeper. The extended receivables collection cycle of 301 days raises concerns about revenue quality and potential collectability issues, suggesting that reported revenues may not convert to cash efficiently. Earnings quality is compromised by reliance on non-operating and extraordinary items rather than core operational profitability.
Full-year guidance projects Revenue of 1.3B yen (YoY +0.9%), Operating Loss of -3.8B yen, Ordinary Loss of -3.4B yen, and Net Loss of -3.5B yen. Current Q3 progress rates stand at Revenue 30.8% and Net Loss 62.9% of full-year guidance. Revenue progress is tracking below the standard 75% completion rate at Q3, suggesting potential downside risk to revenue guidance or anticipated acceleration in Q4. Loss progression at 62.9% indicates that losses may be moderating relative to earlier quarters, though full-year loss guidance remains substantial. The guidance assumes continued operating losses throughout the fiscal year with no path to profitability indicated. Key assumptions from forecast notes emphasize that projections are based on currently available information and reasonable assumptions, with actual results subject to significant variance due to various factors. The company's forecast of -3.5B yen net loss represents continued capital erosion equivalent to 14.5% of current equity base, requiring attention to structural cost reduction and revenue recovery initiatives.
Annual dividend forecast is 0.00 yen with no revision during the quarter. The company maintains a no-dividend policy given the loss-making status and need to preserve capital for operational improvement. Payout ratio is not applicable given net losses. No share buyback activities were disclosed. Total shareholder returns remain zero, reflecting prioritization of financial stability and operational turnaround over capital distributions. The absence of dividends is appropriate given accumulated losses of -10.5B yen in retained earnings and ongoing operational challenges requiring capital preservation.
Revenue contraction risk remains critical with Q3 revenue declining 39.2% YoY to 0.4B yen, indicating fundamental demand challenges or product adoption issues. The company's ability to reverse this decline and achieve modest full-year growth of 0.9% faces execution uncertainty. Cost structure misalignment represents a structural risk with operating losses of -2.5B yen on revenue of 0.4B yen, producing an operating margin of -637.5%. The substantial fixed cost base relative to revenue requires immediate restructuring to establish sustainable economics. Working capital efficiency concerns arise from receivables collection period of 301 days, indicating potential credit quality issues or customer payment challenges that could constrain cash conversion and create additional financial pressure beyond reported operating losses.
[Industry Position] (Reference - Proprietary Analysis) The company operates in the pharmaceutical industry where development-stage dynamics typically produce negative profitability metrics. Profitability: ROE of -9.0% compares favorably to industry median of -35.8% (IQR: -91.4% to -6.1%), suggesting relatively contained losses compared to peers. Operating margin of -637.5% substantially underperforms industry median of -218.2% (IQR: -628.8% to -14.9%), indicating more severe operational challenges than typical sector participants. Financial Health: Equity ratio of 94.4% significantly exceeds industry median of 67.8% (IQR: 62.1% to 79.1%), reflecting conservative capital structure with minimal leverage. Current ratio of 1775.2x far exceeds industry median of 6.62x (IQR: 4.66x to 9.18x), demonstrating exceptional liquidity positioning. Efficiency: Asset turnover of 0.016 underperforms industry median of 0.17 (IQR: 0.05 to 0.24), suggesting lower revenue productivity from asset base. Receivables turnover of 301 days compares unfavorably to industry median of 151.55 days (IQR: 86.75 to 300.82 days), positioning near the upper end of sector collection cycles. Revenue contraction of -39.2% YoY underperforms industry median decline of -12.5% (IQR: -22.1% to -2.5%), indicating more severe top-line challenges than peers. The company's extreme liquidity strength and capital conservation contrast with operational performance that lags sector norms, suggesting a development-stage entity with substantial cash resources but facing commercialization or market acceptance challenges. (Industry: Pharmaceutical (13 companies), Comparison: 2025-Q3 fiscal period, Source: Proprietary analysis)
Substantial liquidity buffer provides runway for operational turnaround with cash and deposits of 24.2B yen covering current liabilities 16.8x and representing 94.6% of total assets, creating financial flexibility to fund restructuring initiatives despite sustained operating losses. The preservation of equity ratio at 94.4% and minimal leverage offers strategic optionality for the company to pursue operational improvements without near-term financial distress concerns. Structural profitability challenge requires urgent attention as operating margin of -637.5% and accelerating loss trajectory (operating loss deterioration of -83.5% YoY) indicate fundamental business model issues beyond normal development-stage dynamics, requiring cost structure realignment and revenue stabilization to establish sustainable path to profitability. Working capital efficiency degradation with receivables collection extending to 301 days signals potential revenue quality concerns or customer creditworthiness issues that warrant monitoring for potential impact on future cash flows and reported revenue sustainability. The reliance on extraordinary income of 3.2B yen to partially offset operating losses highlights the absence of recurring profit generation from core business activities.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.